Which hip claims deserve a second look?

Does feeling better mean my hip was repaired?

No. The ends of bones are capped by cartilage, a smooth covering inside the joint. Less soreness doesn't prove that covering grew back. A person may move more easily while an X-ray still shows the same wear. The reverse can happen too: an X-ray may look worn while daily life remains manageable.

I'd ask, "Are we discussing relief, easier movement or repair?"

A direct answer matters. If the clinician says "regenerate," ask what will be different in your hip. A good answer tells you whether the aim is how you feel or a change inside the joint.

How do I judge a strong treatment claim?

Ask what improved for people in the study: soreness, movement or the joint itself. Then ask whether the study compared the care with no care, another treatment or salt water. Find out how long any relief lasted. One person's good result can be sincere, but it can't tell you what yours will be.

The comparison matters as much as the result.

If someone gives you a success rate, ask where the number came from. Ask whether it was based on hips like yours. Don't let a number hurry you when nobody can explain it plainly.

What should I ask about cost and time?

Get the full cash price before you agree. Ask whether later visits, another treatment, an X-ray or another scan cost extra. You'll want to know how long each visit takes. Find out when you can go back to driving, walking and normal chores. Insurance may not pay, so learn the total before care starts.

Write the answers down.

You don't need to choose during the visit. Ask when the clinician would stop because the care isn't helping. That answer can spare you more time and expense without a clear reason.

What if the answer is still unclear?

QC Kinetix offers regenerative treatment options after an exam. These non-surgical choices can use your own blood. One choice is called concentrated PRP, meaning platelet-rich plasma prepared by spinning your blood sample. Clinic staff keep liquid with extra platelets, small blood parts used in clotting. Joint preservation means trying exercise, lighter activity or non-surgical care before replacing your hip.

Take your questions and any old X-ray report.

Ask what the prepared liquid contains and where it goes. Get the total cost, the visit count and a reason this choice fits your exam. Ask when a talk about surgery would make more sense.

Sources

1. FDA's public list of licensed cellular and gene therapy products is the checkable answer to 'is this FDA-approved?'. A product not on that list, and not being administered under an active IND, is not an approved therapy however it is described in a brochure. For orthopedics the list is short and its cartilage entry is MACI, indicated for focal full-thickness knee defects.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Approved Cellular and Gene Therapy Products. FDA, 2026.

2. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.

3. On 25 June 2019 US District Judge Ursula Ungaro of the Southern District of Florida permanently enjoined US Stem Cell Clinic LLC, US Stem Cell Inc. and their chief scientific officer from manufacturing or distributing stromal vascular fraction products until they comply with the law. The Department of Justice had filed in May 2018; on 3 June 2019 the court granted summary judgment, concluding the defendants had ADULTERATED AND MISBRANDED cellular products made from patients' own adipose tissue. Autologous origin is not a regulatory exemption.

   Sharpless NE (Acting Commissioner of Food and Drugs) — Statement on stem cell clinic permanent injunction and FDA's ongoing efforts to protect patients from risks of unapproved products. FDA Press Announcements, 2019.

4. A randomized trial of 90 patients with KL grade 1-3 knee OA found bone marrow aspirate concentrate - the product most often sold as a 'stem cell injection' - was EQUIVALENT to, not better than, PRP through 24 months, with no statistically significant IKDC or WOMAC difference at any time point. Both arms improved from baseline and plateaued at 3 months.

   Anz AW, et al. — Bone Marrow Aspirate Concentrate Is Equivalent to Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis at 2 Years: A Prospective Randomized Trial.. The American journal of sports medicine, 2022. DOI: 10.1177/03635465211072554.

5. A Level-1a systematic review of 87 randomized PRP-for-knee-OA trials (7,925 patients, 8,118 knees) scored them against the 23-item MIBO reporting checklist. The overall MIBO score was 72%, 71% of studies scored below 80%, and reporting was worst on exactly the items that define the product: whole-blood characteristics (20%), platelet recovery rate (22%), PRP analysis (30%), PRP activation (47%). Adherence did not improve after MIBO was published. Much of the PRP literature does not say what was actually injected.

   Nakagawa HF, et al. — Systematic Review of Randomized Controlled Trials Evaluating the Use of Platelet-Rich Plasma for Knee Osteoarthritis: Adherence to Minimum Information for Studies Evaluating Biologics in Orthopaedics.. The American journal of sports medicine, 2025. DOI: 10.1177/03635465241249996.

6. A GRADE-rated systematic review and meta-analysis of 16 randomized trials (807 participants) found that MSC therapy for chronic knee OA pain PROBABLY RESULTS IN LITTLE TO NO DIFFERENCE in pain relief at 3-6 months (WMD -0.74 cm on a 10 cm VAS against a minimally important difference of 1.5 cm) or physical functioning (WMD 2.23 on the SF-36 100-point subscale against a 10-point MID), both moderate certainty; at 12 months pain was again probably little-to-no-different (WMD -0.73 cm). The measured effect is real but sits BELOW the threshold at which a patient would notice it.

   Sadeghirad B, et al. — Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.. Osteoarthritis and cartilage, 2024. DOI: 10.1016/j.joca.2024.04.021.

7. A meta-analysis of 14 placebo cohorts from 13 Level-1 knee OA injection trials (1,076 patients, KL 1-4) measured what the SALINE arms did. Intra-articular normal saline produced a statistically significant VAS pain improvement at 3 months (MD 12.10) and a larger one at 6 months (MD 16.62), reaching clinically meaningful thresholds. Any uncontrolled report of 'my injection worked' has to clear this bar before it means anything about the injectate.

   Saltzman BM, et al. — The Therapeutic Effect of Intra-articular Normal Saline Injections for Knee Osteoarthritis: A Meta-analysis of Evidence Level 1 Studies.. The American journal of sports medicine, 2017. DOI: 10.1177/0363546516680607.

8. A dual systematic review compared the RCT evidence on injectable orthobiologics for knee OA with how news media describe it. Of 14 qualifying RCTs, 8 showed significant pain improvement and 10 function improvement, with frequent heterogeneity and risk of bias. Of 124 news articles: 79.0% highlighted benefits, only 29.8% mentioned drawbacks, 37.1% used the term 'stem cell' without specifying the product, 35.5% mentioned commercial entities with no disclosure, and 66.1% were favourable in tone. The authors conclude this disconnect encourages unrealistic expectations.

   Zhang EJX, et al. — Disparities in Evidence and Media Portrayal of Injectable Orthobiologics for Knee Osteoarthritis: A Systematic Review of Randomized Trials and News Media.. Orthopaedic journal of sports medicine, 2026. DOI: 10.1177/23259671261443876.